Peter Tebben, MD
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1922085414
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,885 of the $17,488 with a category attached, or 85.1%. Kyowa Kirin, Inc. accounts for 82.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $14,305, more than ten times the $750 reported in 2021.
Across 19 payments — averaging $920.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$14K
- Ascendis Pharma Endocrinology Inc$2K
- AstraZeneca$750
- Tolmar Pharmaceuticals, Inc.$21
Across 35 payments — averaging $1355.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$28K
- AstraZeneca$20K
What the payments were for
- Consulting fees$14,88585%
- Travel & lodging$1,98811%
- Food & beverage$5943%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 16 | $14,457 |
| Ascendis Pharma Endocrinology Inc | 1 | $2,260 |
| AstraZeneca | 1 | $750 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRYSVITA$14,088
How this compares
$17,488 in reported general payments places this provider in the 85th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 49 | $203,516 |
| Teriparatide | 33 | $85,856 |
| TymlosAbaloparatide | 12 | $30,860 |
| Alendronate Sodium | 77 | $944 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $624 |
| Levothyroxine Sodium | 18 | $290 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New Haven
- Ania JastreboffNew Haven$536K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Richard KibbeyNew Haven$18K
- Surani FernandoNew Haven$13K
- Irina RosewaterNew Haven$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.